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ATAC = Arimidex, Tamoxifen Alone or in Combination; EORTC = European Organization for Research and Treatment of Cancer; EUSOMA =
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Principle.
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The 4th European Breast Cancer Conference was held in
Hamburg, Germany on 16–20 March 2004. This joint
meeting, organized under the auspices of the European
Organization for Research and Treatment of Cancer
(EORTC) Breast Cancer Group, of the European Breast
Cancer Coalition (Europa Donna) and of the European
Society of Mastology (EUSOMA), was attended by 3599
participants (clinicians, scientists and patient advocates)
from 82 countries. There were well over 500
presentations on new developments in molecular biology,
epidemiology, prevention, diagnosis, treatment, supportive
care and the psychosocial and quality-of-life aspects of
breast cancer. In addition, there was a special focus on
the role of patient advocates and breast cancer support
groups. The leading theme of this conference was
partnership: the partnership among scientists, clinicians,
carers, advocates and patients.
The scientific program was initiated by Martine Piccart
from Brussels, with her Emmanuel van der Schueren
opening ceremony lecture on tailored adjuvant treatments
of early breast cancer. Switching from empirical treatment
to individually designed approaches based on specific
molecular profiles may soon become a realistic prospect.
The gene profiling technology based on microarray assays
will hopefully allow for a better selection of candidates for
systemic adjuvant treatment and for individualized
chemotherapy.
These possibilities are currently being tested in a number
of prospective randomized trials, including the EORTC
10994 study (the role of p53 gene mutation in predicting
response to anthracycline-based chemotherapy versus
taxane-based chemotherapy) and the Trial of Principle
(TOP; addressing the impact of topoisomerase II alpha
expression on response to anthracycline chemotherapy) —
both in the setting of locally advanced disease.
The most important question, however, is the putative
possibility of avoiding any adjuvant chemotherapy in the
subgroups of patients with a ‘favorable’ gene signature.
Such an approach might spare the toxicity and cost of
adjuvant chemotherapy in at least 20% of patients,
without influencing the overall prognosis. This hypothesis
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will soon be tested in a large prospective randomized trial
(Microarray for Node Negative Disease may Avoid Chemo-
therapy; MINDACT) run by the Breast International Group.
This study will compare the outcome of adjuvant
chemotherapy in patients assigned to treatment on the
grounds of current standard clinical criteria versus
assigned according to molecular signature. Microarray
technology is also expected to allow for selection of
patients for dose-dense chemotherapy or other forms of
intensified treatment.
The role of gene expression profiling techniques in
recognition of specific cell properties was also addressed
in other papers presented at the conference. Biostatistical
analysis of gene expression allows for identification of
specific ‘expression signatures’ associated with particular
clinical endpoints [1,2]. After validation in sufficiently large
series of patients, this technology, as well as other
emerging genomics and proteomics techniques, may find
wide application in the diagnosis of breast cancer. The
first example of potentially routine use of gene expression
profiling, using a standardized device developed for use at
local pathology laboratories (Breast Cancer ProfileChip,
Ipsogen SAS, Marseille, France), was presented by
French researchers. The use of gene profiling and
microarray technology also allows for identification of new
subsets of breast cancer with distinct biology and
prognosis. A newly recognized important entity, apart from
previously described luminal and basal type carcinomas [3],
is apocrine carcinoma, which is characterized by positive
androgen receptor status and negative estrogen receptor
status. These results create the possibility of using
androgen suppression in the treatment of selected tumors.
One of the conference highlights was a joint presentation
of three recently published randomized trials addressing
the role of aromatase inhibitors in the adjuvant treatment
of early breast cancer: the Arimidex, Tamoxifen Alone or in
Combination (ATAC) study (anastrozole versus tamoxifen
versus combination administered for 5 years after local
treatment ± chemotherapy), the MA17 study (5-year
administration of letrozole versus placebo after 5 years of
tamoxifen treatment), and the most recently published
International Exemestane Study (exemestane versus
tamoxifen for 2–3 years after 2–3 years of tamoxifen)
[4–6]. The latter two studies were presented for the first
time at a large scientific meeting. All these studies
demonstrated the notable advantage of aromatase
inhibitors in terms of disease-free survival. This led to
premature termination of these trials and early disclosure
of their results.
These recently published studies were also subjected to
lively discussion in two Oxford-style debates on the role of
aromatase inhibitors in adjuvant treatment of breast
cancer and problems related to early presentation of
clinical trials. The notion of the outdated role of tamoxifen
was proposed and defended by W Jonat from Kiel,
Germany (seconded by P Lønning, Bergen, Norway), and
was opposed by K Pritchard from Toronto, Canada
(seconded by H Thornton, Colchester, UK). Although
adjuvant aromatase inhibitor administration seems to
provide notable benefit, follow-up of these trials was too
short to assess reliably the effect of the whole planned
intervention.
The only trial that will hopefully provide this information in
the future is the International Exemestane Study as, by the
time of its closure, more than 90% of patients had finished
protocol treatment. The other two studies were closed
prematurely with many patients crossing over to
aromatase inhibitor treatment, thus clouding its impact on
long-term results (including survival). Furthermore, the
data on long-term toxicity of aromatase inhibitors are still
missing. Finally, the optimal scheduling of these
compounds remains undetermined, as all three studies
used them in a different time frame and setting. Some data
may suggest that the size of the benefit rises with longer
use of tamoxifen preceding the aromatase inhibitor. This
can possibly be explained by tamoxifen-induced
sensitization of tumor cells to aromatase inhibitors, or by
the gradually decreasing effect of tamoxifen (possibly
related to its agonistic effect) and the reversal of this
process by aromatase inhibitors.
Another controversial and hotly debated issue was early
presentation of clinical trials. The opponents included two
distinguished biostatisticians (D Berry, Houston, TX, USA,
in favor of early disclosure; and R Gelber, Boston, MA,
USA, against early disclosure), seconded by two trialists
(respectively, J O’Shaughnessy, Dallas, TX, USA and I
Tannock, Toronto, Canada). Potential disadvantages of
early publications, apart from the previously mentioned
incomplete data on late outcomes and toxicity, include
their detrimental effect on the conduct of other clinical
studies addressing similar issues. Caution must also be
paid to the interpretation of early positive results, as this
effect may disappear or even reverse with time. Another
potential danger is a possible publication bias, as positive
studies are more likely to be published sooner. The
appearance of a significant difference or an otherwise
clinically relevant result early in the course of a trial also
creates an important ethical dilemma of releasing these
results to patients. Their early switching to potentially
beneficial treatment may cloud long-term comparative
analysis, and must be weighed against a policy of continuing
the study for the benefit of future patients and society.
A series of other important clinical studies on endocrine
therapy was presented at the conference. The EORTC
10863 study demonstrated no benefit (in terms of overall
survival) of intermittent tamoxifen administration or alter-150
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nating tamoxifen/medroxyprogesterone acetate administra-
tion, compared with standard continuous tamoxifen
administration. The EORTC 10951 trial comparing
exemestane and tamoxifen in the first-line treatment of
advanced disease demonstrated an apparent superiority
of exemestane in terms of response rate (44% versus
29%) and time to progression (median, 10.9 months and
6.7 months, respectively). At the same time, no adverse
effect on lipid profiles, observed in studies of nonsteroidal
aromatase inhibitors, was found. Results of the EORTC
10901 study including more than 1800 patients confirmed
prospectively the disease-free survival advantage associated
with a 3-year tamoxifen treatment following adjuvant chemo-
therapy in operable breast cancer. The IMPACT (IMmediate
Preoperative Arimidex, tamoxifen or Combined with
Tamoxifen) and PROACT (PReOperative Arimidex
(anastrozole) Compared with Tamoxifen) trials failed to
demonstrate a significant advantage of preoperative
anastrozole compared with tamoxifen in locally advanced/
large operable tumors, although some benefit may be
confined to selected endpoints and subgroups of patients.
The area of clinical research arousing major interest over
the past years and widely discussed during the
conference was primary chemotherapy. With efficacy
proven to be equivalent to adjuvant therapy [7,8], this
setting not only offers increased rates of breast conserva-
tion, but also creates an ideal experimental model for in
vivo  predictive assays of various treatments including
targeting factors. The most important areas of clinical
research include the use of noncross-resistant taxane-
based regimens of chemotherapy [9,10], dose-dense
chemotherapy schedules [11] and the use of aromatase
inhibitors. The question remains, however, whether
particular surrogate endpoints (such as the rate of
pathological complete remission) are reliable predictors of
late results. Such correlations might facilitate and
significantly shorten the evaluation of adjuvant systemic
therapies. New research directions in this group of
patients include development of diagnostic tools for early
prediction of response (such as magnetic resonance
imaging or positron emission tomography) and monitoring
of treatment-induced molecular changes in tumor cells.
An important part of the discussion on new chemotherapy
strategies included the dose-dense approach, a strategy
believed to offer the chance of overcoming tumor re-
growth between consecutive cycles. Indeed, early results
of the Intergroup Trial C9741/Cancer and Leukemia Group
B Trial 9741 demonstrated a significant improvement in
disease-free and overall survival in node-positive patients
administered dose-dense adjuvant chemotherapy [11].
Other approaches to overcoming tumor resistance include
the incorporation of noncross-resistant drugs (in
particular, taxanes). Of interest were the updated results
of the BCIRG001 study, demonstrating maintained
disease-free and overall survival advantage of the taxane-
based regimen (docetaxel + doxorubicin + cyclophospha-
mide) over the standard 5-fluorouracil + doxorubicin +
cyclophosphamide regimen in adjuvant treatment of node-
positive patients.
A landmark paper by Slamon and colleagues [12] was the
first to demonstrate a significant advantage associated
with the addition of trastuzumab to paclitaxel in advanced
breast cancer. New evidence for the role of trastuzumab
comes from the updated results of the M77001 study,
showing 8-month median survival improvement in Her2-
positive metastatic disease patients administered trastuzu-
mab and docetaxel, compared with docetaxel alone. The
results of ongoing studies addressing the use of trastuzu-
mab in the adjuvant setting are awaited with great interest.
Changing trends in breast cancer treatment include better
understanding of the different biology of two main breast
cancer subtypes: hormone-responsive breast cancer and
hormone-independent breast cancer. This phenomenon is
reflected by higher rates of response to chemotherapy in
hormone-independent tumors [9] and, on the contrary, in a
shift away from adjuvant chemotherapy in receptor-
positive patients. Data were presented on the relationship
between hormone receptor level and benefit from addition
of chemotherapy to tamoxifen in the adjuvant treatment,
demonstrating no advantage from combined treatment in
patients with moderate and high hormone receptor
concentrations.
A few studies recently indicated higher response rates
and/or prolonged disease-free survival associated with
aromatase inhibitor therapy compared with tamoxifen in
progesterone receptor-negative tumors and ErbB-1-
positive and/or ErbB-2 positive tumors [13]. These
findings may provide a basis for the selection of relatively
small subgroups of patients deriving a large benefit from
adjuvant aromatase inhibitors, saving society the high cost
of treatment of the remaining patients, in whom tamoxifen
may prove equally effective.
An intriguing, although not fully understood, piece of
information came from the Dutch study on cardiovascular
mortality following breast cancer treatment. Although in
the whole population of breast cancer survivors the risk of
cardiovascular death was within the range of normal
expectancy, cardiovascular mortality was significantly
decreased in a subgroup of nonirradiated patients in
comparison with the general population. A possible explana-
tion for this phenomenon is that the risk profile for breast
cancer or a healthier lifestyle after breast cancer diagnosis
may be protective against cardiovascular morbidity.
Two interesting and important observations regarding
standards of breast cancer care were presented. The first,151
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coming from a large Canadian population-based study,
confirmed decreased mortality (hazard ratio, 0.7) in
patients managed in concordance with accepted
guidelines and treated at centers dealing with large
numbers of cases. Particular gain (hazard ratio, 0.4) was
attributed to participation in clinical trials. The other
analysis, including postmenopausal patients treated within
the International Exemestane Study, demonstrated large
differences in the frequency of breast conservation rates
between countries, ranging from 2% in Poland to 72% in
France. Possible explanations for this observation include
differences in stage distribution related to efficacy of
nationwide screening programs, tradition, and surgeons’
and patients’ attitudes. Further analyses are warranted to
fully elucidate this phenomenon.
The conference was, as usual, concluded by the inter-
active plenary session on critical issues in breast cancer,
leading to the development of the Hamburg Statement.
This document will set out the directions for breast cancer
research and care for the next 2 years. The first problem
discussed was threats and constraints to academic
research, possibly leading to a shift towards industry-
oriented studies and to abandoning other areas of clinical
research, such as diagnosis, surgery and radiotherapy. A
call was made for more determined financial and structural
support for academic research, facilitation of free
circulation of tissue and blood samples within the
European Union for research purposes, and a greater
involvement of patients and consumers in research
planning and monitoring [14].
Another issue addressed in this session was the limited
consideration of special needs of elderly patients,
reflected by their restricted inclusion in clinical trials. It
was postulated that participation in these trials should be
based on physiological status rather than on age, and that
no upper age limit should be laid down in the design of
standard prevention and treatment plans. Recommenda-
tions were also made on the need of professional care for
high-risk women and on providing full free-of-charge
genetic counseling and testing for women with a strong
family history of breast cancer [14].
Finally, a plea for improvements in care for breast cancer
survivors was made. Apart from detecting local tumor
recurrence and second malignancies, this should include
psychological support and the management of late
treatment sequelae [14].
The 5th European Breast Cancer Conference will be held
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